Literature DB >> 30972469

Determination of berberine-upregulated endogenous short-chain fatty acids through derivatization by 2-bromoacetophenone.

Shu-Rong Ma1, Qian Tong2, Zhen-Xiong Zhao1, Lin Cong1, Jin-Bo Yu1, Jie Fu1, Pei Han1, Li-Bin Pan1, Randy Gu1, Ran Peng1, Zheng-Wei Zhang1, Yan Wang3, Jian-Dong Jiang4.   

Abstract

Short-chain fatty acids (SCFAs) are a major group of endogenous metabolites generated by the gut microbiota and have been reported to play an important role in physical health, such as improving energy metabolism. Here, using 2-bromoacetophenone as the derivatization reagent (BP, 10 mg/mL, 40 °C for 20 min), a sensitive liquid chromatography-tandem mass spectrometric method was established for the quantitative determination of seven short-chain fatty acids in plasma and feces. The analyses were performed on a C18 column in positive multiple reaction monitoring mode. Specificity, linearity, accuracy, precision, recovery, and stability were observed within the quantitative limits of biological sample analysis. The established method has largely improved the sensitivity by 200- to 2000-fold than that in gas chromatography (GC). Especially for butyrate, the lower quantitative limit of 1 ng/mL, 1600-fold higher in sensitivity than that of GC (1.6 μg/mL), ensured the accurate determination of its low level in blood or feces (88 ± 29 ng/mL in blood, 176 ± 18 μg/g in feces). Then, the validated method was applied for therapeutic studies of berberine in hyperlipidemia hamsters in vivo and screening of 13 compounds (including five metabolites of berberine and eight typical isoquinoline alkaloids) in vitro. After berberine treatment (oral, 200 mg/kg, 2 weeks) to hyperlipidemia hamsters, the levels of butyrate were significantly upregulated in blood (77 ± 10 ng/mL vs. 117 ± 13 ng/mL, *P < 0.05) and feces (132 ± 11 μg/g vs. 547 ± 57 μg/g, ***P < 0.001), which further verified butyrate as an active endogenous metabolite in coordination with berberine to lower the blood lipids. Additionally, the berberine metabolites (M1, M2, M3), as well as two isoquinoline alkaloids (tetrandrine and dauricine), could also obviously induce the production of SCFAs (butyrate, etc.) in gut microbiota. In total, we have successfully established a new derivative LC-MS/MS method for the targeted quantitative determination of seven SCFAs in biological samples. Graphical abstract.

Entities:  

Keywords:  2-Bromoacetophenone; Berberine; Butyrate; Derivatization; Isoquinoline alkaloids; LC-MS/MS

Mesh:

Substances:

Year:  2019        PMID: 30972469     DOI: 10.1007/s00216-019-01793-3

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  4 in total

1.  Berberine treats atherosclerosis via a vitamine-like effect down-regulating Choline-TMA-TMAO production pathway in gut microbiota.

Authors:  Shu-Rong Ma; Qian Tong; Yuan Lin; Li-Bin Pan; Jie Fu; Ran Peng; Xian-Feng Zhang; Zhen-Xiong Zhao; Yang Li; Jin-Bo Yu; Lin Cong; Pei Han; Zheng-Wei Zhang; Hang Yu; Yan Wang; Jian-Dong Jiang
Journal:  Signal Transduct Target Ther       Date:  2022-07-07

Review 2.  Liquid Chromatography-Mass Spectrometry (LC-MS) Derivatization-Based Methods for the Determination of Fatty Acids in Biological Samples.

Authors:  Christiana Mantzourani; Maroula G Kokotou
Journal:  Molecules       Date:  2022-09-05       Impact factor: 4.927

Review 3.  Multi-Pharmacology of Berberine in Atherosclerosis and Metabolic Diseases: Potential Contribution of Gut Microbiota.

Authors:  Shengjie Yang; Dan Li; Zongliang Yu; Yujuan Li; Min Wu
Journal:  Front Pharmacol       Date:  2021-07-09       Impact factor: 5.810

Review 4.  The Association Between Intestinal Bacteria and Allergic Diseases-Cause or Consequence?

Authors:  Pei Han; Jian-Qing Gu; Li-Sha Li; Xue-Yan Wang; Hong-Tian Wang; Yan Wang; Christopher Chang; Jin-Lyu Sun
Journal:  Front Cell Infect Microbiol       Date:  2021-04-15       Impact factor: 5.293

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.